The efficacy validation of mTOR inhibitor in oncology (renal cancer, pancreatic NETs, breast cancer, etc) naturally leads to increase their use,[22–25] especially everolimus, an oral therapy usually well tolerated in comparison with cytotoxic chemotherapy.[26] Physicians need to recognize everolimus toxicities, given is efficacy in metastatic breast cancer. This evidence concerns the gene MTOR and renal carcinoma.